Sydney Lepkin

Eli Lilly is announcing that early results from a Phase 3 clinical trial of its GLP-1 pill show it reduced participants' A1c, a measure of blood sugar control, better than placebo. The trial lasted 40 weeks and was only for people with type 2 diabetes. According to the company, the safety and efficacy was consistent with its injectable GLP-1 drugs, Zepbound and Manjaro.

Eli Lilly is announcing that early results from a Phase 3 clinical trial of its GLP-1 pill show it reduced participants' A1c, a measure of blood sugar control, better than placebo. The trial lasted 40 weeks and was only for people with type 2 diabetes. According to the company, the safety and efficacy was consistent with its injectable GLP-1 drugs, Zepbound and Manjaro.

The once-daily pill also helped patients lose up to 16 pounds. The company plans to report the results at the American Diabetes Association conference and publish them in a peer-reviewed medical journal later this year. Sydney Lepkin, NPR News.

The once-daily pill also helped patients lose up to 16 pounds. The company plans to report the results at the American Diabetes Association conference and publish them in a peer-reviewed medical journal later this year. Sydney Lepkin, NPR News.